VERONA PHARMA P/S (NASDAQ:VRNA) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 700 shares, a decline of 22.2% from the May 30th total of 900 shares. Based on an average daily trading volume, of 3,900 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are short sold.
A number of brokerages have issued reports on VRNA. Wedbush set a $20.00 target price on Plymouth Industrial Reit and gave the stock a “buy” rating in a research report on Monday, May 20th. BTIG Research set a $14.00 target price on ARBOR RLTY TR I/SH and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Zacks Investment Research cut German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.00.
A hedge fund recently raised its stake in VERONA PHARMA P/S stock. Wedbush Securities Inc. raised its holdings in shares of VERONA PHARMA P/S (NASDAQ:VRNA) by 75.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,800 shares of the company’s stock after buying an additional 10,670 shares during the quarter. Wedbush Securities Inc. owned about 0.19% of VERONA PHARMA P/S worth $161,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.09% of the company’s stock.
VERONA PHARMA P/S stock traded up $0.25 during trading hours on Thursday, reaching $5.10. 6,700 shares of the company were exchanged, compared to its average volume of 7,788. The firm has a market capitalization of $71.23 million, a price-to-earnings ratio of -2.52 and a beta of -1.00. The firm has a 50-day moving average price of $5.66. VERONA PHARMA P/S has a 12 month low of $4.82 and a 12 month high of $14.50.
VERONA PHARMA P/S (NASDAQ:VRNA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.04. Equities research analysts forecast that VERONA PHARMA P/S will post -2.33 earnings per share for the current year.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Featured Article: What are popular green investing opportunities?
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.